Aethlon Medical Receives Full Ethics Approval for Prostate Cancer Trial

Pindara Private Hospital's Human Research Ethics Committee Grants Approval

Study to Evaluate Novel Therapeutic Approach for Prostate Cancer

SAN DIEGO, June 18, 2024 - Nasdaq: AEMD) Aethlon Medical, Inc., a clinical-stage biopharmaceutical company focused on developing innovative therapies for cancer and rare diseases, today announced that it has received full ethics approval from the Human Research Ethics Committee at Bellberry Private Hospital in Australia for its Phase 2 clinical trial evaluating the use of its novel therapeutic approach in the treatment of prostate cancer.

The trial, known as the ATLAS Study, will evaluate the safety and efficacy of Aethlon's proprietary Hemopurifier in combination with standard of care therapy in patients with metastatic prostate cancer who have failed prior treatment with androgen deprivation therapy. The Hemopurifier is designed to remove circulating tumor cells (CTCs) from the bloodstream, which play a key role in the development and progression of cancer. By removing CTCs, the Hemopurifier aims to improve treatment outcomes by reducing tumor burden and preventing the formation of new tumors.

"We are excited to have received full ethics approval for our ATLAS Study and are grateful to the Bellberry Human Research Ethics Committee for their support," said Dr. Jeffrey A. Matos, Chief Executive Officer of Aethlon Medical. "This trial represents a significant milestone in our efforts to develop innovative therapies for prostate cancer patients who currently have limited treatment options."

The ATLAS Study is expected to enroll approximately 120 patients at up to 20 clinical sites in Australia, the United States, and Europe. The study will be led by Dr. Matos, who has extensive experience in the development of novel cancer therapies and has previously led several successful clinical trials in prostate cancer.

"The ATLAS Study is a well-designed trial that has the potential to provide important new insights into the role of CTCs in prostate cancer and the potential benefits of our Hemopurifier technology," said Dr. Matos. "We are confident that the trial will provide valuable data that will enable us to further advance the development of our therapy and ultimately improve outcomes for patients with this devastating disease.